

SCORE other Mega Item Details for

[Score Home](#) [Page Retrieve Application List](#) [SCORE System Overview](#) [SCORE FAQ](#) [Comments / Sugg](#)

This page gives you Mega Item detail for the Application 10071826 and Item 20061207-10071826.
[start](#) | [next page](#)

```

{\rtf1\ansi\ansicpg1252\uc1 \deflang1033\deflangfe1033{\fonttbl{\f0\fr
{\f2\fmmodern\fcharset0\frpq1{\*\panose 02070309020205020404}Courier New;}{\f3\froman\fcharset2\frpq2{\*\pan
{\f5\fwiss\fcharset0\frpq2{\*\panose 00000000000000000000}Helvetica;}{\f6\fmmodern\fcharset0\frpq1{\*\panos
{\f8\froman\fcharset0\frpq2{\*\panose 00000000000000000000}Tms Rmn;}{\f9\fwiss\fcharset0\frpq2{\*\panose 0
{\f11\fwiss\fcharset0\frpq2{\*\panose 00000000000000000000}MS Sans Serif;}{\f12\froman\fcharset0\frpq2{\*\
{\f14\fnil\fcharset2\frpq2{\*\panose 05000000000000000000}Wingdings;}{\f15\froman\fcharset128\frpq1{\*\panc
{\f17\fnil\fcharset134\frpq2{\*\panose 00000000000000000000}SimSun{\*\falt ??}};{\f18\fnil\fcharset136\frp
{\f20\fmmodern\fcharset129\frpq1{\*\panose 00000000000000000000}Dotum{\*\falt ??}};{\f21\fmmodern\fcharset134
{\f23\froman\fcharset128\frpq1{\*\panose 00000000000000000000}MS Mincho{\*\falt MS ??}};{\f24\froman\fhars
{\f25\fmmodern\fcharset128\frpq1{\*\panose 00000000000000000000}MS Gothic{\*\falt MS ???}};{\f26\froman\fh
{\f28\froman\fcharset238\frpq2 Times New Roman CE;}{\f29\froman\fcharset204\frpq2 Times New Roman Cyr;}{\f3
{\f33\froman\fcharset177\frpq2 Times New Roman (Hebrew);}{\f34\froman\fcharset178\frpq2 Times New Roman (Ar
{\f39\fwiss\fcharset161\frpq2 Arial Greek;}{\f40\fwiss\fcharset162\frpq2 Arial Tur;}{\f41\fwiss\fcharset
{\f44\fmmodern\fcharset238\frpq1 Courier New CE;}{\f45\fmmodern\fcharset204\frpq1 Courier New Cyr;}{\f47\fmoc
{\f50\fmmodern\fcharset178\frpq1 Courier New (Arabic);}{\f51\fmmodern\fcharset186\frpq1 Courier New Baltic;}}
\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\
ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \fs24\lang1033\langfe1033\cgrid\l
\qc\tx4320\tqr\tx8640\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \fs24\lang1033\langfe1033\cgrid\l
\qc\tx4320\tqr\tx8640\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \fs24\lang1033\langfe1033\cgrid\l
{\creatim\yr2006\mo12\dy7\hr10\min10}{\revtim\yr2006\mo12\dy7\hr10\min11}{\version2}{\edmins1}{\nofpages104
\widowctrl\ftnbj\aeenddoc\noxlattoyen\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\hyphcaps0\horzdoc\dghspace
{\header \pard\plain \s15\qc \li0\ri0\widctlpar\qc\tx4320\tqr\tx8640\aspalpha\aspnum\faauto\adjustright\ri
\par }}{\footer \pard\plain \s16\ql \li0\ri0\widctlpar\qc\tx4320\tqr\tx8640\pvppara\pvmrg\posxc\posy0\aspal
\cs17\lang1024\langfe1024\noproof 104}}}{\cs17
\par }{\pard \s16\ql \li0\ri0\widctlpar\qc\tx4320\tqr\tx8640\aspalpha\aspnum\faauto\adjustright\rin0\lin0\it
\par }}{\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang{\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent7
{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnclctr\pnstart1\pninde
\pnclctr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang
{\pntxta .}}{\*\pnseclvl10\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl11\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl12\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl13\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl14\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl15\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl16\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl17\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl18\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl19\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl20\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl21\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl22\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl23\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl24\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl25\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl26\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl27\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl28\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl29\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl30\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl31\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl32\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl33\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl34\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl35\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl36\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl37\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl38\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl39\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl40\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl41\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl42\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl43\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl44\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl45\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl46\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl47\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl48\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl49\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl50\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl51\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl52\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl53\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl54\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl55\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl56\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl57\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl58\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl59\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl60\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl61\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl62\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl63\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl64\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl65\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl66\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl67\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl68\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl69\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl70\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl71\pnlcltr\pnstart1\pnindent720\pnhang{\pntxtb (}{\pntxta )}}{\*\pnseclvl72\pnlcl
```

```

\par (L38 OR L22)
\par L43 6866 SEA FILE=MEDLINE ABB=ON PLU=ON ("BOTULINUM TOXIN TYPE
\par A"/CN OR "BOTULINUM TOXIN TYPE B"/CN OR "BOTULINUM TOXIN
\par TYPE C"/CN OR "BOTULINUM TOXIN TYPE D"/CN OR "BOTULINUM
\par TOXIN TYPE E"/CN OR "BOTULINUM TOXIN TYPE F"/CN OR
\par "BOTULINUM TOXIN TYPE G"/CN OR "BOTULINUM TOXINS"/CN)
\par L44 QUE ABB=ON PLU=ON "BOTULINUM TOXIN TYPE A"+PFT,NT/CT
\par L45 4712 SEA FILE=MEDLINE ABB=ON PLU=ON "BOTULINUM TOXINS"/CT
\par L46 24 SEA FILE=MEDLINE ABB=ON PLU=ON (L43 OR L44 OR L45) AND
\par (L38 OR L22)
\par L47 35 SEA FILE=MEDLINE ABB=ON PLU=ON L39 OR L46
\par L48 21 SEA FILE=MEDLINE ABB=ON PLU=ON L47 NOT (MILK? OR TURK?
\par OR INFANT? OR FEED?)/TI
\par L49 9 SEA FILE=MEDLINE ABB=ON PLU=ON L48 AND (AY<2000 OR
\par PY<2000 OR PRY<2000 OR MY<2000)
\par
\par
\par => d que 162
\par L3 1 SEA FILE=REGISTRY ABB=ON PLU=ON 93384-43-1/RN
\par L4 1 SEA FILE=REGISTRY ABB=ON PLU=ON 93384-44-2/RN
\par L5 1 SEA FILE=REGISTRY ABB=ON PLU=ON 93384-45-3/RN
\par L6 1 SEA FILE=REGISTRY ABB=ON PLU=ON 93384-46-4/RN
\par L7 1 SEA FILE=REGISTRY ABB=ON PLU=ON 93384-47-5/RN
\par L8 1 SEA FILE=REGISTRY ABB=ON PLU=ON 107231-12-9/RN
\par L9 1 SEA FILE=REGISTRY ABB=ON PLU=ON 107231-15-2/RN
\par L10 1 SEA FILE=REGISTRY ABB=ON PLU=ON 107231-16-3/RN
\par L11 1 SEA FILE=REGISTRY ABB=ON PLU=ON 107231-13-0 /RN
\par L12 10 SEA FILE=REGISTRY ABB=ON PLU=ON (L3 OR L4 OR L5 OR L6 OR
\par L7 OR L8 OR L9 OR L10 OR L*** OR L11)
\par L13 1 SEA FILE=REGISTRY ABB=ON PLU=ON L12 AND KINAS?
\par L14 9 SEA FILE=REGISTRY ABB=ON PLU=ON L12 NOT L13
\par L15 28 SEA FILE=REGISTRY ABB=ON PLU=ON BOTULINUM?/CN
\par L22 QUE ABB=ON PLU=ON MAMMARY(W) (GLAND? OR LOBULE? OR EPIT
\par HEL? OR ALVEOL?) OR BREAST
\par L56 4786 SEA FILE=EMBASE ABB=ON PLU=ON L14
\par L57 4786 SEA FILE=EMBASE ABB=ON PLU=ON L15
\par L58 QUE ABB=ON PLU=ON "BOTULINUM NEUROTOXIN F"+PFT,NT/CT
\par L59 QUE ABB=ON PLU=ON "BOTULINUM TOXIN"+PFT,NT/CT
\par L60 QUE ABB=ON PLU=ON "MAMMARY GLAND"+PFT,NT/CT
\par L61 51 SEA FILE=EMBASE ABB=ON PLU=ON (L56 OR L57 OR L58 OR L59)
\par AND (L60 OR L22)
\par L62 11 SEA FILE=EMBASE ABB=ON PLU=ON L61 AND (AY<2000 OR
\par PY<2000 OR PRY<2000)
\par
\par
\par
\par (FILE 'BIOSIS, DRUGU, BIOTECHNO, VETU' ENTERED AT 12:25:56 ON 06 DEC
\par 2006)
\par
\par
\par => d que 179
\par L3 1 SEA FILE=REGISTRY ABB=ON PLU=ON 93384-43-1/RN
\par L4 1 SEA FILE=REGISTRY ABB=ON PLU=ON 93384-44-2/RN
\par L5 1 SEA FILE=REGISTRY ABB=ON PLU=ON 93384-45-3/RN
\par L6 1 SEA FILE=REGISTRY ABB=ON PLU=ON 93384-46-4/RN
\par L7 1 SEA FILE=REGISTRY ABB=ON PLU=ON 93384-47-5/RN
\par L8 1 SEA FILE=REGISTRY ABB=ON PLU=ON 107231-12-9/RN
\par L9 1 SEA FILE=REGISTRY ABB=ON PLU=ON 107231-15-2/RN
\par L10 1 SEA FILE=REGISTRY ABB=ON PLU=ON 107231-16-3/RN
\par L11 1 SEA FILE=REGISTRY ABB=ON PLU=ON 107231-13-0 /RN
\par L12 10 SEA FILE=REGISTRY ABB=ON PLU=ON (L3 OR L4 OR L5 OR L6 OR
\par L7 OR L8 OR L9 OR L10 OR L*** OR L11)
\par L13 1 SEA FILE=REGISTRY ABB=ON PLU=ON L12 AND KINAS?
\par L14 9 SEA FILE=REGISTRY ABB=ON PLU=ON L12 NOT L13
\par L15 28 SEA FILE=REGISTRY ABB=ON PLU=ON BOTULINUM?/CN
\par L22 QUE ABB=ON PLU=ON MAMMARY(W) (GLAND? OR LOBULE? OR EPIT
\par HEL? OR ALVEOL?) OR BREAST
\par L38 QUE ABB=ON PLU=ON "MAMMARY GLANDS, ANIMAL"+PFT,NT,OLD.
\par NT/CT
\par L66 1550 SEA L14
\par L67 1550 SEA L15
\par L68 1342 SEA ("BOTULINUM TOXIN"/CN OR "BOTULINUM TOXIN A"/CN OR
\par "BOTULINUM TOXIN B"/CN OR "BOTULINUM TOXIN C1"/CN OR
\par "BOTULINUM TOXIN D"/CN OR "BOTULINUM TOXIN E"/CN OR
\par "BOTULINUM TOXIN F"/CN OR "BOTULINUM TOXIN TYPE A"/CN OR
\par "BOTULINUM TOXIN TYPE B"/CN OR "BOTULINUM TOXIN TYPE-A"/CN
\par OR "BOTULINUM TOXIN-A"/CN OR "BOTULINUM TOXIN-D"/CN OR

```

```

\par "BOTULINUM TOXIN/A"/CN OR "BOTULINUM TOXINS"/CN OR
\par "BOTULINUM TYPE A TOXIN"/CN OR "BOTULINUM-A TOXIN"/CN)
\par L69 3 SEA ("BOTULINUM NEUROTOXIN A"/CN OR "BOTULINUM NEUROTOXIN
\par TYPE A"/CN)
\par L70 1417 SEA E3+ALL
\par L71 140 SEA E3+ALL
\par L72 3019 SEA (L66 OR L67 OR L68 OR L69 OR L70 OR L71)
\par L75 7 SEA L72 AND (L38 OR L22)
\par L79 2 SEA L75 AND (AY<2000 OR PY<2000 OR PRY<2000)
\par
\par
\par
\par (FILE 'DRUGB, LIFESCI, SCISEARCH, PASCAL, BIOENG, JAPIO, JICST-EPLUS,
\par VETB' ENTERED AT 13:13:38 ON 06 DEC 2006)
\par
\par
\par }{{f2\fs20\lang1036\langfe1033\langnp1036 => d que 185
\par L19 QUE ABB=ON PLU=ON BOTULINUM(W)NEUROTOXIN OR BOTULINUM
\par }{{f2\fs20 (W)TOXIN OR BOTULIN?
\par L22 QUE ABB=ON PLU=ON MAMMARY(W) (GLAND? OR LOBULE? OR EPIT
\par HEL? OR ALVEOL?) OR BREAST
\par L83 64 SEA L19 AND L22
\par L84 36 SEA L83 AND (AY<2000 OR PY<2000 OR PRY<2000)
\par L85 14 SEA L84 NOT (CHICK? OR TURK? OR INFANT? OR FEED? OR
\par COOK?)/TI
\par
\par
\par }{{f2\fs20\lang1036\langfe1033\langnp1036 => d que 1104
\par L19 QUE ABB=ON PLU=ON BOTULINUM(W)NEUROTOXIN OR BOTULINUM
\par }{{f2\fs20 (W)TOXIN OR BOTULIN?
\par L22 QUE ABB=ON PLU=ON MAMMARY(W) (GLAND? OR LOBULE? OR EPIT
\par HEL? OR ALVEOL?) }{{f2\fs20\lang1036\langfe1033\langnp1036 OR BREAST
\par L31 QUE ABB=ON PLU=ON BRIN, M7/AU
\par L32 QUE ABB=ON PLU=ON DONOVAN, S7/AU
\par L92 QUE ABB=ON PLU=ON A61K039-08/IPC
\par L93 QUE ABB=ON PLU=ON A61K0039-08/IPC
\par L94 QUE ABB=ON PLU=ON (A61P035-00 OR A61P0015-00)/IPC
\par }{{f2\fs20 L95 7 SEA FILE=WPIX ABB=ON PLU=ON L19(30A)L22
\par L96 3 SEA FILE=WPIX ABB=ON PLU=ON L95 NOT (L31 OR L32)
\par L97 16 SEA FILE=WPIX ABB=ON PLU=ON L22 AND (L92 OR L93)
\par L98 8 SEA FILE=WPIX ABB=ON PLU=ON L97 AND L94
\par L99 5 SEA FILE=WPIX ABB=ON PLU=ON L98 NOT (L31 OR L32)
\par L100 28 SEA FILE=WPIX ABB=ON PLU=ON L19 AND L94
\par L101 8 SEA FILE=WPIX ABB=ON PLU=ON L100 AND L22
\par L102 41 SEA FILE=WPIX ABB=ON PLU=ON (L95 OR L96 OR L97 OR L98 OR
\par L99 OR L100 OR L101)
\par L104 17 SEA FILE=WPIX ABB=ON PLU=ON L102 AND (AY<2000 OR PY<2000
\par OR PRY<2000)
\par
\par
\par
\par => dup rem 190 149 162 179 185 1104
\par FILE 'HCAPLUS' ENTERED AT 15:03:17 ON 06 DEC 2006
\par USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
\par PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
\par COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
\par
\par
\par FILE 'MEDLINE' ENTERED AT 15:03:17 ON 06 DEC 2006
\par
\par
\par FILE 'EMBASE' ENTERED AT 15:03:17 ON 06 DEC 2006
\par Copyright (c) 2006 Elsevier B.V. All rights reserved.
\par
\par
\par FILE 'BIOSIS' ENTERED AT 15:03:17 ON 06 DEC 2006
\par Copyright (c) 2006 The Thomson Corporation
\par
\par
\par FILE 'BIOTECHNO' ENTERED AT 15:03:17 ON 06 DEC 2006
\par COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.
\par
\par
\par FILE 'LIFESCI' ENTERED AT 15:03:17 ON 06 DEC 2006
\par COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)
\par
\par
\par
\par FILE 'SCISEARCH' ENTERED AT 15:03:17 ON 06 DEC 2006
\par Copyright (c) 2006 The Thomson Corporation
\par
\par
\par FILE 'PASCAL' ENTERED AT 15:03:17 ON 06 DEC 2006
\par Any reproduction or dissemination in part or in full,

```

[illegible]

```

\par ED Entered STN: 11 Feb 2005
\par }\pard \ql \fi-666\li666\ri0\widctlpar\tx666\faauto\adjustright\rin0\lin666\itap0 {\f2\fs20 AB \tab
The present invention relates to methods for treating atypical tissues, such as hyperplastic tissues, cysts
nting the development of, or for causing the regression or remission of, atypical tissues, cysts and neopla
\b\f2\fs20\cf6 gland}\f2\fs20 disorders, such as }\b\f2\fs20\cf6 mammary}\f2\fs20 }\b\f2\fs20\cf6 gla
cysts and neoplasms) both benign and cancerous, as well as for treating hyperplastic and / or hypertonic c
\par }\pard \ql \li0\ri0\nowidctlpar\faauto\rin0\lin0\itap0 {\f2\fs20 IC ICM A61K039-08
\par INCL 424239100
\par CC 1-6 (Pharmacology)
\par ST diverse cancer }\b\f2\fs20\cf6 mammary}\f2\fs20 }\b\f2\fs20\cf6 gland}\f2\fs20 }\b\f2\fs20
\par }\b\f2\fs20\cf6 toxin}\f2\fs20
\par IT }\b\f2\fs20\cf6 Mammary gland, neoplasm}\f2\fs20
\par (fibroadenoma; methods for treating diverse cancers)
\par
\par L106 ANSWER 2 OF 43 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2
\par ACCESSION NUMBER: 2005:248644 HCAPLUS }\field{\*\fldinst {\f2\fs20 HYPERLINK
"http://chemport.cas.org/cgi-bin/ex_sdcgi?uuZguK@lruXN9uqAdMVTRx59jvJlQBUMfxaczUW0JM3I@lIwCme@YJpnmQJF3AU4
{\*\datafield
00d0c9ea79f9bace118c8200aa004ba90b0200000003000000e0c9ea79f9bace118c8200aa004ba90bd801000068007400740070003
750075005a00670075004b00400031007200750078004e00390075007100410064004d005600540052007800350039006a0076004ac
0052006e007200490079004c0076006e003500400031005500700076006b006a004600590052003300710078006b005700420043007
6a00680075007000480053004c00340040005a004d0062005800650078007100390036006600780047005500560046003500480032c
0072004000780000000}}{\fldrslt {\f2\fs20\ul\cf2 Full-text}}{\v\f2\fs20 <<LOGINID::20061206>>}\f2\fs20
\par DOCUMENT NUMBER: 142:274057
\par TITLE: Sequences of human schizophrenia related genes and
\par use for diagnosis, prognosis and therapy
\par INVENTOR(S): Liew, Choong-chin
\par PATENT ASSIGNEE(S): Chondrogene Limited, Can.
\par SOURCE: U.S. Pat. Appl. Publ., 156 pp., Cont.-in-part of
\par U.S. Ser. No. 802,875.
\par }\f2\fs20\lang1036\langfe1033\langnp1036 CODEN: USXXCO
\par DOCUMENT TYPE: Patent
\par }\f2\fs20 LANGUAGE: English
\par FAMILY ACC. NUM. COUNT: 47
\par PATENT INFORMATION:
\par
\par PATENT NO. KIND DATE APPLICATION NO. DATE
\par -----
\par US 2004241727 A1 20041202 US 2004-812731 20040330
\par <--
\par US 2004014059 A1 20040122 US 2002-268730 20021009
\par <--
\par US 2005191637 A1 20050901 US 2004-803737 20040318
\par <--
\par US 2005196762 A1 20050908 US 2004-803759 20040318
\par <--
\par US 2005196763 A1 20050908 US 2004-803857 20040318
\par <--
\par US 2005196764 A1 20050908 US 2004-803858 20040318
\par <--
\par US 2005208505 A1 20050922 US 2004-803648 20040318
\par <--
\par US 2004241727 A1 20041202 US 2004-812731 20040330
\par <--
\par PRIORITY APPLN. INFO.: US 1999-115125P P 19990106
\par <--
\par US 2000-477148 B1 20000104
\par
\par US 2002-268730 A2 20021009
\par
\par US 2003-601518 A2 20030620
\par
\par US 2004-802875 A2 20040312
\par
\par US 2004-812731 A 20040330
\par
\par ED Entered STN: 23 Mar 2005
\par }\pard \ql \fi-666\li666\ri0\widctlpar\tx666\faauto\adjustright\rin0\lin666\itap0 {\f2\fs20 AB \tab Th
ir equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood f
y
which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes a
t record is one of 3 records for this document necessitated by the large number of index entries required t
\par }\pard \ql \li0\ri0\nowidctlpar\faauto\rin0\lin0\itap0 {\f2\fs20\lang1036\langfe1033\langnp1036 IC 1
\par }\f2\fs20 INCL 435006000
\par CC 1-11 (Pharmacology)
\par Section cross-reference(s): 3, 6, 7, 9, 13

```

```

\par IT Proteins
\par (BRAP1 (}{\b\f2\fs20\cf6 breast}{\f2\fs20 cancer-associated protein 1); sequences of
\par human schizophrenia-related genes and use for diagnosis, prognosis
\par and therapy)
\par IT Tumor antigens
\par (NY-BR-20, serol. defined }{\b\f2\fs20\cf6 breast}{\f2\fs20 cancer; sequences of
\par human schizophrenia-related genes and use for diagnosis, prognosis
\par and therapy)
\par IT Proteins
\par (}{\b\f2\fs20\cf6 breast}{\f2\fs20 carcinoma amplified sequence 2; sequences of
\par human schizophrenia-related genes and use for diagnosis, prognosis
\par and therapy)
\par IT Proteins
\par (ras-related C3 }{\b\f2\fs20\cf6 botulinum}{\f2\fs20 }{\b\f2\fs20\cf6 toxin}{\f2\fs20 substr
\par sequences of human schizophrenia-related genes and use for
\par diagnosis, prognosis and therapy)
\par
\par L106 ANSWER 3 OF 43 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3
\par ACCESSION NUMBER: - 2002:540137 HCAPLUS }{\field{\*\fldinst {\f2\fs20 HYPERLINK "http://chempc
BCzHL0UjhnJFumbs_WVLegyVChd5cZRM8Xg7_uZjhupHSL4@ZMnXexq96fxGUVF5HGLkHhoa5VnCGbvy7lrqXWN@9rmnBxjAbklxMZir@x"
00d0c9ea79f9bace118c8200aa004ba90b0200000003000000e0c9ea79f9bace118c8200aa004ba90bd801000068007400740070003
750075005a00670075004b00400031007200750078004e00390075007100710064004d005600540052007800350039006a0076004aC
0052006e007200490079004c0076006e003500400031005500700076006b0067004600590052003300710078006b005700420043007
6a00680075007000480053004c00340040005a004d006e005800650078007100390036006600780047005500560046003500480047C
007200400078000000}}{\fldrslt {\f2\fs20\ul\cf2 Full-text}}}{\v\f2\fs20 <<LOGINID::20061206>>}}{\f2\fs20
\par DOCUMENT NUMBER: 137:73251
\par TITLE: Methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20
}{\b\f2\fs20\cf6 gland}{\f2\fs20 disorders
\par INVENTOR(S): Brin, Mitchell F.; Donovan, Stephen
\par PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
\par SOURCE: U.S. Pat. Appl. Publ., 19 pp., Cont.-in-part of
U.S. Ser. No. 631,221.
\par }{\f2\fs20\lang1036\langfe1033\langnp1036 CODEN: USXXCO
\par DOCUMENT TYPE: Patent
\par }{\f2\fs20 LANGUAGE: English
\par FAMILY ACC. NUM. COUNT: 4
\par PATENT INFORMATION:
\par
\par PATENT NO. KIND DATE APPLICATION NO. DATE
\par -----
\par US 2002094339 A1 20020718 US 2002-71826 20020208
\par <--
\par US 6139845 A 20001031 US 1999-454842 19991207
\par <--
\par CA 2478902 AA 20040826 CA 2003-2478902 20030204
\par WO 2004071525 A1 20040826 WO 2003-US3479 20030204
\par W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
\par CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
\par GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
\par LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
\par NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ,
\par TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
\par RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
\par BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
\par }{\f2\fs20\lang1036\langfe1033\langnp1036 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL,
\par SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
\par SN, TD, TG
\par AU 2003225549 A1 20040906 AU 2003-225549 20030204
\par }{\f2\fs20 EP 1492561 A1 20050105 EP 2003-815338 20030204
\par EP 1492561 B1 20060628
\par R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
\par PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
\par BR 2003007496 A 20050628 BR 2003-7496 20030204
\par }{\f2\fs20\lang1036\langfe1033\langnp1036 JP 2006510723 T2 20060330 JP 2004-568252
\par }{\f2\fs20 AT 331527 E 20060715 AT 2003-815338 20030204
\par US 2005031648 A1 20050210 US 2004-929040 20040827
\par <--
\par US 2005260231 A1 20051124 US 2005-192777 20050729
\par <--
\par PRIORITY APPLN. INFO.: US 1999-454842 A2 19991207
\par <--
\par US 2000-631221 A2 20000802
\par
\par US 2002-71826 A 20020208
\par
\par WO 2003-US3479 W 20030204

```

```

\par
\par ED Entered STN: '19 Jul 2002
\par \pard \ql \fi-666\li666\ri0\widctlpar\tx666\faauto\adjustright\rin0\lin666\itap0 {\f2\fs20 AB \tab A
disorder, including hyperplastic, hypertonic, cystic and/or neoplastic }{\b\f2\fs20\cf6 mammary}{\f2\fs20
to or to the vicinity of the afflicted }{\b\f2\fs20\cf6 breast}{\f2\fs20 tissue is described.
\par \pard \ql \li0\ri0\nowidctlpar\faauto\rin0\lin0\itap0 {\f2\fs20 IC ICM A61K039-08
\par INCL 424247100
\par CC 1-6 (Pharmacology)
\par ST treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20 }{\b\f2\fs20\cf6 gland}{\f2\fs20 disorder }{\b\f2\fs20
\par }{\b\f2\fs20\cf6 toxin}{\f2\fs20
\par IT Proteins
\par (DP (docking protein), as substrate for }{\b\f2\fs20\cf6 botulinum}{\f2\fs20
\par }{\b\f2\fs20\cf6 toxin}{\f2\fs20 ; methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20 }{\f2\fs20
\par disorders)
\par IT Proteins
\par (SNAP-25 (synaptosome-associated protein, 25 kDa), as substrate for
\par }{\b\f2\fs20\cf6 botulinum}{\f2\fs20 }{\b\f2\fs20\cf6 toxin}{\f2\fs20 ; methods for treating
\par }{\b\f2\fs20\cf6 mammary}{\f2\fs20 }{\b\f2\fs20\cf6 gland}{\f2\fs20 disorders)
\par IT Synaptobrevins
\par Syntaxins
\par (as substrate for }{\b\f2\fs20\cf6 botulinum}{\f2\fs20 }{\b\f2\fs20\cf6 toxin}{\f2\fs20 ; met
\par treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20 }{\b\f2\fs20\cf6 gland}{\f2\fs20 disorders)
\par IT }{\b\f2\fs20\cf6 Mammary gland, disease}{\f2\fs20
\par (blunt duct adenosis; methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20
\par }{\b\f2\fs20\cf6 gland}{\f2\fs20 disorders)
\par IT Exocytosis
\par ({\b\f2\fs20\cf6 botulinum}{\f2\fs20 }{\b\f2\fs20\cf6 toxin}{\f2\fs20 inhibiting vesicle-me
\par from hyperplastic tissue; methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20
\par }{\b\f2\fs20\cf6 gland}{\f2\fs20 disorders)
\par IT }{\b\f2\fs20\cf6 Mammary gland, neoplasm}{\f2\fs20
\par (carcinoma; methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20 }{\b\f2\fs20\cf6 gland}{\f2\fs20
\par disorders)
\par IT }{\b\f2\fs20\cf6 Mammary gland, disease}{\f2\fs20
\par (cyst; methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20 }{\b\f2\fs20\cf6 gland}{\f2\fs20
\par disorders)
\par IT }{\b\f2\fs20\cf6 Mammary gland, disease}{\f2\fs20
\par (duct papilloma; methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20
\par }{\b\f2\fs20\cf6 gland}{\f2\fs20 disorders)
\par IT }{\b\f2\fs20\cf6 Mammary gland, neoplasm}{\f2\fs20
\par (fibroadenoma; methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20 }{\b\f2\fs20\cf6 gland
\par disorders)
\par IT }{\b\f2\fs20\cf6 Mammary gland, disease}{\f2\fs20
\par (hyperplasia; methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20 }{\b\f2\fs20\cf6 gland}{\f2\fs20
\par disorders)
\par IT }{\b\f2\fs20\cf6 Mammary gland, disease}{\f2\fs20
\par (hypertonic; methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20 }{\b\f2\fs20\cf6 gland}{\f2\fs20
\par disorders)
\par IT Drug delivery systems
\par (implants; methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20 }{\b\f2\fs20\cf6 gland}{\f2\fs20
\par disorders)
\par IT Drug delivery systems
\par (injections; methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20 }{\b\f2\fs20\cf6 gland}{\f2\fs20
\par disorders)
\par IT Adenoma
\par (mammary fibroadenoma; methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20
\par }{\b\f2\fs20\cf6 gland}{\f2\fs20 disorders)
\par IT Carcinoma
\par Cyst, pathological
\par Hyperplasia
\par (mammary; methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20 }{\b\f2\fs20\cf6 gland}{\f2\fs20
\par disorders)
\par IT Human
\par }{\b\f2\fs20\cf6 Mammary gland}{\f2\fs20
\par }{\b\f2\fs20\cf6 Mammary gland, disease}{\f2\fs20
\par }{\b\f2\fs20\cf6 Mammary gland, neoplasm}{\f2\fs20
\par (methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20 }{\b\f2\fs20\cf6 gland}{\f2\fs20 di
\par IT Clostridium
\par }{\b\f2\fs20\cf6 Clostridium botulinum}{\f2\fs20
\par ({\b\f2\fs20\cf6 neurotoxin}{\f2\fs20 of; methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20
\par }{\b\f2\fs20\cf6 gland}{\f2\fs20 disorders)
\par IT Toxins
\par (neurotoxins, of Clostridium; methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20
\par }{\b\f2\fs20\cf6 gland}{\f2\fs20 disorders)
\par IT }{\b\f2\fs20\cf6 Mammary gland, disease}{\f2\fs20
\par (proliferative; methods for treating }{\b\f2\fs20\cf6 mammary}{\f2\fs20
\par }{\b\f2\fs20\cf6 gland}{\f2\fs20 disorders)

```

```

\par IT  }}{\b\f2\fs20\cf6 Mammary gland, disease}}{\f2\fs20
\par      (sclerosing adenosis; methods for treating }}{\b\f2\fs20\cf6 mammary}}{\f2\fs20
\par      }}{\b\f2\fs20\cf6 gland}}{\f2\fs20 disorders)
\par IT  }}{\b\f2\fs20\cf6 93384-43-1}}{\f2\fs20 , }}{\b\f2\fs20\cf6 Botulin}}{\f2\fs20 A }}{\b\f2\fs20\cf6 93
\par      }}{\b\f2\fs20\cf6 Botulin}}{\f2\fs20 B }}{\b\f2\fs20\cf6 93384-45-3}}{\f2\fs20 , }}{\b\f2\fs20\cf6 Bc
\par      }}{\b\f2\fs20\cf6 93384-46-4}}{\f2\fs20 , }}{\b\f2\fs20\cf6 Botulin}}{\f2\fs20 D }}{\b\f2\fs20\cf6 93
\par      }}{\b\f2\fs20\cf6 Botulin}}{\f2\fs20 E }}{\b\f2\fs20\cf6 107231-12-9}}{\f2\fs20 , }}{\b\f2\fs20\cf6 E
\par      }}{\b\f2\fs20\cf6 107231-15-2}}{\f2\fs20 , }}{\b\f2\fs20\cf6 Botulin}}{\f2\fs20 F }}{\b\f2\fs20\cf6 1
\par      }}{\b\f2\fs20\cf6 Botulin}}{\f2\fs20 G
\par      (methods for treating }}{\b\f2\fs20\cf6 mammary}}{\f2\fs20 }}{\b\f2\fs20\cf6 gland}}{\f2\fs20 di
\par IT  }}{\b\f2\fs20\cf6 93384-43-1}}{\f2\fs20 , }}{\b\f2\fs20\cf6 Botulin}}{\f2\fs20 A }}{\b\f2\fs20\cf6 93
\par      }}{\b\f2\fs20\cf6 Botulin}}{\f2\fs20 B }}{\b\f2\fs20\cf6 93384-45-3}}{\f2\fs20 , }}{\b\f2\fs20\cf6 Bc
\par      }}{\b\f2\fs20\cf6 93384-46-4}}{\f2\fs20 , }}{\b\f2\fs20\cf6 Botulin}}{\f2\fs20 D }}{\b\f2\fs20\cf6 93
\par      }}{\b\f2\fs20\cf6 Botulin}}{\f2\fs20 E }}{\b\f2\fs20\cf6 107231-12-9}}{\f2\fs20 , }}{\b\f2\fs20\cf6 E
\par      }}{\b\f2\fs20\cf6 107231-15-2}}{\f2\fs20 , }}{\b\f2\fs20\cf6 Botulin}}{\f2\fs20 F }}{\b\f2\fs20\cf6 1
\par      }}{\b\f2\fs20\cf6 Botulin}}{\f2\fs20 G
\par      (methods for treating }}{\b\f2\fs20\cf6 mammary}}{\f2\fs20 }}{\b\f2\fs20\cf6 gland}}{\f2\fs20 di
\par RN  93384-43-1 HCAPLUS
\par CN  Botulin A (9CI) (CA INDEX NAME)
\par
\par *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
\par RN  93384-44-2 HCAPLUS
\par CN  Botulin B (9CI) (CA INDEX NAME)
\par
\par *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
\par RN  93384-45-3 HCAPLUS
\par CN  Botulin C (9CI) (CA INDEX NAME)
\par
\par *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
\par RN  93384-46-4 HCAPLUS
\par CN  Botulin D (9CI) (CA INDEX NAME)
\par
\par *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
\par RN  93384-47-5 HCAPLUS
\par CN  Botulin E (9CI) (CA INDEX NAME)
\par
\par *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
\par RN  107231-12-9 HCAPLUS
\par CN  Botulin (9CI) (CA INDEX NAME)
\par
\par *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
\par RN  107231-15-2 HCAPLUS
\par CN  Botulin F (9CI) (CA INDEX NAME)
\par
\par *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
\par RN  107231-16-3 HCAPLUS
\par CN  Botulin G (9CI) (CA INDEX NAME)
\par
\par *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
\par
\par L106 ANSWER 4 OF 43. HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 4
\par ACCESSION NUMBER: 1999:614258 HCAPLUS }}{\field{*}\fldinst {\f2\fs20 HYPERLINK
"http://chemport.cas.org/cgi-bin/ex_sdcgi?uuZguK@lrxN9uqHdMVTRx59jvJlQBumfxaczUW0JM3I@1IeCme@YJpnmQJF3AU4
{*\datafield
00d0c9ea79f9bace118c8200aa004ba90b0200000003000000e0c9ea79f9bace118c8200aa004ba90bd801000068007400740070003
750075005a00670075004b00400031007200750078004e00390075007100480064004d005600540052007800350039006a0076004ac
0052006e007200490079004c0076006e003500400031005500700076006b0035004600590052003300710078006b005700420043007
6a00680075007000480053004c00340040005a004d006b00580065007800710039003600710078006b005500510046003300480079c
007200400078000000}}{\fldrslt {\f2\fs20\ul\cf2 Full-text}}}}{\v\f2\fs20 <<LOGINID::20061206>>}}{\f2\fs20
\par DOCUMENT NUMBER: 131:227652
\par TITLE: Human monoclonal antibodies from tetroma cells
\par INVENTOR(S): Trakht, Ilya
\par PATENT ASSIGNEE(S): The Trustees of Columbia University In the City of
\par New York, USA
\par SOURCE: PCT Int. }}{\f2\fs20\lang1036\langfe1033\langnp1036 Appl., 86 pp.
\par CODEN: PIXXD2
\par DOCUMENT TYPE: Patent
\par }}{\f2\fs20 LANGUAGE: English
\par FAMILY ACC. NUM. COUNT: 1
\par PATENT INFORMATION:
\par
\par PATENT NO. KIND DATE APPLICATION NO. DATE
\par -----
\par WO 9947929 A1 19990923 WO 1999-US5828 19990318
\par
\par <--
\par W: AU, CA, JP, MX, US

```



```

\par      RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
\par      NL, PT, SE
\par      US 6197582      B1      20010306      US 1998-40833      19980318
\par      CA 2323681      AA      19990923      CA 1999-2323681      19990318
\par      AU 9931889      A1      19991011      AU 1999-31889      19990318
\par      EP 1064551      A1      20010103      EP 1999-913925      19990318
\par      R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
\par      JP 2002507398      T2      20020312      JP 2000-537073      19990318
\par      PRIORITY APPLN. INFO.:      US 1998-40833      A2 19980318
\par      WO 1999-US5828      W 19990318
\par      ED Entered STN: 26 Sep 1999
\par } \pard \ql \fi-666\li666\ri0\widctlpar\tx666\faauto\adjustright\rin0\lin666\itap0 {\f2\fs20 AB \tab Th
reparation of antibody-non-producing heteromyeloma and trioma cells from the fusion of human and mouse myel
u
cing a monoclonal antibody having specific binding affinity for antigen. The invention thus provides a met
pplication of these tetroma-derived monoclonal antibodies.
\par } \pard \ql \li0\ri0\nowidctlpar\faauto\rin0\lin0\itap0 {\f2\fs20 IC ICM G01N033-53
\par ICS G01N033-567; C07K016-00; A61K039-395; A61K039-42
\par CC 15-1 (Immunochemistry)
\par Section cross-reference(s): 1, 8, 14, 63
\par IT Immunoglobulins
\par (M, monoclonal; to ) {\b\f2\fs20\cf6 breast} {\f2\fs20 and prostate cancer antigens)
\par IT Antitumor agents
\par ( ) {\b\f2\fs20\cf6 mammary} {\f2\fs20 } {\b\f2\fs20\cf6 gland} {\f2\fs20 ; tetroma-derived monocl
antibodies as)
\par IT ) {\b\f2\fs20\cf6 Mammary gland} {\f2\fs20
} {\b\f2\fs20\cf6 Mammary gland} {\f2\fs20
\par Prostate gland
\par Prostate gland
\par (neoplasm, inhibitors; tetroma-derived monoclonal antibodies as)
\par IT ) {\b\f2\fs20\cf6 107231-12-9} {\f2\fs20 , } {\b\f2\fs20\cf6 Botulin} {\f2\fs20
(tetroma-derived monoclonal antibodies as therapy against)
\par IT ) {\b\f2\fs20\cf6 107231-12-9} {\f2\fs20 , } {\b\f2\fs20\cf6 Botulin} {\f2\fs20
(tetroma-derived monoclonal antibodies as therapy against)
\par RN 107231-12-9 HCAPLUS
\par CN Botulin (9CI) (CA INDEX NAME)
\par *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
\par REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT
\par L106 ANSWER 5 OF 43 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 5
\par ACCESSION NUMBER: 1999:538764 HCAPLUS ) {\field{*fldinst {\f2\fs20 HYPERLINK "http://chempc
e@YJpnmqJF3AU4RnrIyLvn5@1UpvkPPYR3qXkWBCzHLOUjhnJFumbs_WVLegypChD5c2Rm8Xg7_uZjhupHSL4@ZMwXexq96qXkUQF3HyLkH
00d0c9ea79f9bace118c8200aa004ba90b0200000003000000e0c9ea79f9bace118c8200aa004ba90bd801000068007400740070003
750075005a00670075004b00400031007200750078004e00390075007100500064004d005600540052007800350039006a0076004ac
0052006e007200490079004c0076006e003500400031005500700076006b0050004600590052003300710078006b005700420043007
6a00680075007000480053004c00340040005a004d007700580065007800710039003600710078006b005500510046003300480079c
007200400078000000} } {\fldrslt {\f2\fs20\ul\cf2 Full-text} } } {\v\f2\fs20 <<LOGINID::20061206>>} {\f2\fs20
\par DOCUMENT NUMBER: 132:48332
\par TITLE: Rho-Kinase (ROK) promotes CD44v3,8-10-ankyrin
interaction and tumor cell migration in metastatic
\par ) {\b\f2\fs20\cf6 breast} {\f2\fs20 cancer cells
\par AUTHOR(S): Bourguignon, Lilly Y. W.; Zhu, Hongbo; Shao,
Lijun; Zhu, Dan; Chen, You-Wei
\par CORPORATE SOURCE: Department of Cell Biology and Anatomy, University
of Miami Medical School, Miami, FL, USA
\par SOURCE: Cell Motility and the Cytoskeleton ( ) {\b\f2\fs20\cf6 1999} {\f2\fs20
), 43(4), 269-287
\par CODEN: CMCYEO; ISSN: 0886-1544
\par PUBLISHER: Wiley-Liss, Inc.
\par DOCUMENT TYPE: Journal
\par LANGUAGE: English
\par ED Entered STN: 27 Aug 1999
\par } \pard \ql \fi-666\li666\ri0\widctlpar\tx666\faauto\adjustright\rin0\lin666\itap0 {\f2\fs20 AB \tab Me
tumor Met-1 cells express CD44v3,8-10, a major adhesion receptor that binds extracellular matrix component
have determined that CD44v3,8-10 and RhoA GTPases are phys. associated in vivo, and that CD44v3,8-10-bound

```

C3-mediated ADP-ribosylation. In addition, the authors have identified a 160-kDa Rho-Kinase (ROK) as one of the downstream targets for CD44v3,8-10-bound RhoA GTPase. Specifically, ROK. Most importantly, phosphorylation of CD44v3,8-10 by ROK enhances its interaction with the cytoskeletal protein constitutively active form of ROK containing the catalytic domain (CAT, also the kinase domain)], and 173 amino acids promotes CD44-ankyrin associated membrane ruffling and projections. This membrane motility can be blocked in Met-1 cells with ROK's Rho-binding (RB) domain cDNA effectively inhibits CD44-ankyrin-mediated metastatic interaction and RhoA-mediated oncogenic signaling required for membrane-cytoskeleton function and metastasis.

Section cross-reference(s): 7, 13

ST: CD44 breast cancer metastasis CD44 RhoA GTPase Rho kinase; CD44 antigen complex RhoA GTPase Rho kinase stimulation

IT: CD44 (antigen)

CD44v3,8-10; rho-Kinase (ROK) promotes CD44v3,8-10-ankyrin interaction and tumor cell migration in metastatic CD44 breast cancer cells

IT: Protein motifs

(catalytic domain; rho-Kinase (ROK) promotes CD44v3,8-10-ankyrin interaction and tumor cell migration in metastatic CD44 breast cancer cells)

IT: Cell membrane

Cytoskeleton

(membrane-cytoskeleton function; rho-Kinase (ROK) promotes CD44v3,8-10-ankyrin interaction and tumor cell migration in metastatic CD44 breast cancer cells)

IT: CD44 Mammary gland

(neoplasm; rho-Kinase (ROK) promotes CD44v3,8-10-ankyrin interaction and tumor cell migration in metastatic CD44 breast cancer cells)

IT: Rho protein (G protein)

(p21rhoA; rho-Kinase (ROK) promotes CD44v3,8-10-ankyrin interaction and tumor cell migration in metastatic CD44 breast cancer cells)

IT: Cell migration

Cytoplasm

Extracellular matrix

Signal transduction, biological

(rho-Kinase (ROK) promotes CD44v3,8-10-ankyrin interaction and tumor cell migration in metastatic CD44 breast cancer cells)

IT: Rho protein (G protein)

(rho-Kinase (ROK) promotes CD44v3,8-10-ankyrin interaction and tumor cell migration in metastatic CD44 breast cancer cells)

IT: Ankyrins

(rho-Kinase (ROK) promotes CD44v3,8-10-ankyrin interaction and tumor cell migration in metastatic CD44 breast cancer cells)

IT: 9059-32-9, GTPase

(of RhoA protein; rho-Kinase (ROK) promotes CD44v3,8-10-ankyrin interaction and tumor cell migration in metastatic CD44 breast cancer cells)

IT: 51845-53-5, Rho kinase

(rho-Kinase (ROK) promotes CD44v3,8-10-ankyrin interaction and tumor cell migration in metastatic CD44 breast cancer cells)

REFERENCE COUNT: 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L106 ANSWER 6 OF 43 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 1999:201389 HCAPLUS

bin/ex_sdcgi?uuZguK@lruXN9uq3dMVTRx59jvJlQBumfxaczUW0JM3I@1IuCmeoYJpnmQJF3AU4RnrIyLvn5@1UpvkMFYR3qgxkWBCzHL00d0c9ea79f9bace118c8200aa004ba90b0200000003000000e0c9ea79f9bace118c8200aa004ba90bd801000068007400740070003750075005a00670075004b00400031007200750078004e00390075007100330064004d005600540052007800350039006a0076004ac0052006e007200490079004c0076006e003500400031005500700076006b004d004600590052003300710078006b0057004200430076a00680075007000480053004c00340040005a004d005700580065007800710039003600710078006b005500510046003300480079c007200400078000000}}{\fldrslt {\f2\fs20\ul\cf2 Full-text}}{\v\fs20 <<LOGINID::20061206>>}}{\f2\fs20

DOCUMENT NUMBER: 131:42807

TITLE: Activation of protein kinase C by phorbol esters modulates CD44 breast cancer cells

AUTHOR(S): Rosfjord, Edward C.; Maemura, Michio; Johnson, Michael D.; Torri, Jeffery A.; Akiyama, Steven K.; Woods, Virgil L., Jr.; Dickson, Robert B.

CORPORATE SOURCE: Lombardi Cancer Research Center, Georgetown University, Washington, DC, 20007, USA

\par SOURCE: Experimental Cell Research ({}{}b{}f2{}fs20{}cf6 1999){}f2{}fs20 {} ,
 \par 248(1), 260-271
 \par CODEN: ECREAL; ISSN: 0014-4827
 \par PUBLISHER: Academic Press
 \par DOCUMENT TYPE: Journal
 \par LANGUAGE: English
 \par ED Entered STN: 30 Mar 1999
 \par } \pard \ql \fi-666\li666\ri0\widctlpar\tx666\fauto\adjustright\rin0\lin666\itap0 {}f2{}fs20 AB \tab Ce
 on of cancer. In this study, the authors investigated the role of protein kinase C (PKC) in the regulator
 adenocarcinoma cell line MCF-7. A PKC activator, 12-O- tetradecanoylphorbol-1,3-acetate (TPA), stimulated
 {}field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2}{{}f2{}fs20 {}field{*\fldir
 \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2 and anti-{}f2{}fs20 {}field{*\fldinst SYMBOL 98 \f "Symbol" \s 1
 1 blocking antibodies each completely abrogated the TPA-induced adhesion. FACS anal. determined that TPA t
 {}f2{}fs20 {}field{*\fldinst SYMBOL 98 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 1 integrin over a
 {}field{*\fldinst SYMBOL 98 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 1 levels were increased afte
 {}f2{}fs20 {}field{*\fldinst SYMBOL 98 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 1-dependent cellul
 {}field{*\fldinst SYMBOL 98 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 1 cell surface expression.
 2 and {}f2{}fs20 {}field{*\fldinst SYMBOL 98 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 1 subunits
 {}f3{}fs20}}{}f2{}fs20 2}{{}f2{}fs20 {}field{*\fldinst SYMBOL 98 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2\
 SYMBOL 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2}{{}f2{}fs20 {}field{*\fldinst SYMBOL 98 \f "S
 \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2}{{}f2{}fs20 {}field{*\fldinst SYMBOL 98 \f "Symbol" \s 10}{\fldrsl
 }{}f2{}fs20 {}field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2}{{}f2{}fs20 {}fie
 "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2}{{}f2{}fs20 {}field{*\fldinst SYMBOL 98 \f "Symbol" \s 10
 possible mechanism by which TPA could be acting to promote the rapid induction of {}f2{}fs20 {}field{*\fldc
 {}f2{}fs20 1 adhesion, the authors treated the cells with the Rho-GTPase inhibitor Clostridium {}b{}f2{}fs20{}c
 hibited TPA-induced adhesion to laminin and collagen I in a dose-dependent manner, suggesting a likely role
 \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2}{{}f2{}fs20 {}field{*\fldinst SYMBOL 98 \f "Symbol" \s 10}{\fldrsl
 {}field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2 and {}f2{}fs20 {}field{*\f
 "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2}{{}f2{}fs20 {}field{*\fldinst SYMBOL 98 \f "Symbol" \s 10
 \par } \pard \ql \li0\ri0\nowidctlpar\fauto\rin0\lin0\itap0 {}f2{}fs20 CC 14-1 (Mammalian Pathological Bic
 \par ST {}b{}f2{}fs20{}cf6 breast){}f2{}fs20 cancer adhesion alpha2betal integrin protein kinase C
 \par IT Animal cell line
 \par (MCF-7; activation of protein kinase C by phorbol esters modulates
 \par {}f2{}fs20 {}field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2){\
 \par {}b{}f2{}fs20{}cf6 breast){}f2{}fs20 cancer cells by altering gene expression of
 \par {}f2{}fs20 {}field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2){\
 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2){{}f2{}fs20 {}field{*\fldinst SYMBOL 98 \f "Symbol"
 \par Rho-dependent adhesion)
 \par IT Cell adhesion
 \par (activation of protein kinase C by phorbol esters modulates
 \par {}f2{}fs20 {}field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2){\
 \par {}b{}f2{}fs20{}cf6 breast){}f2{}fs20 cancer cells by altering gene expression of
 \par {}f2{}fs20 {}field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2){\
 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2){{}f2{}fs20 {}field{*\fldinst SYMBOL 98 \f "Symbol"
 \par Rho-dependent adhesion)
 \par IT mRNA
 \par (activation of protein kinase C by phorbol esters modulates
 \par {}f2{}fs20 {}field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2){\
 \par {}b{}f2{}fs20{}cf6 breast){}f2{}fs20 cancer cells by altering gene expression of
 \par {}f2{}fs20 {}field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2){\
 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2){{}f2{}fs20 {}field{*\fldinst SYMBOL 98 \f "Symbol"
 \par Rho-dependent adhesion)
 \par IT Gene, animal
 \par Rho protein (G protein)
 \par (activation of protein kinase C by phorbol esters modulates
 \par {}f2{}fs20 {}field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2){\
 \par {}b{}f2{}fs20{}cf6 breast){}f2{}fs20 cancer cells by altering gene expression of
 \par {}f2{}fs20 {}field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2){\
 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2){{}f2{}fs20 {}field{*\fldinst SYMBOL 98 \f "Symbol"
 \par Rho-dependent adhesion)
 \par IT {}b{}f2{}fs20{}cf6 Mammary gland){}f2{}fs20
 \par (adenocarcinoma; activation of protein kinase C by phorbol esters
 \par modulates {}f2{}fs20 {}field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2
 \par MCF-7 {}b{}f2{}fs20{}cf6 breast){}f2{}fs20 cancer cells by altering gene expression of
 \par {}f2{}fs20 {}field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2){\
 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2){{}f2{}fs20 {}field{*\fldinst SYMBOL 98 \f "Symbol"
 \par Rho-dependent adhesion)
 \par IT Extracellular matrix
 \par (adhesion to; activation of protein kinase C by phorbol esters
 \par modulates {}f2{}fs20 {}field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2
 \par MCF-7 {}b{}f2{}fs20{}cf6 breast){}f2{}fs20 cancer cells by altering gene expression of
 \par {}f2{}fs20 {}field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2){\
 97 \f "Symbol" \s 10}{\fldrslt{}f3{}fs20}}{}f2{}fs20 2){{}f2{}fs20 {}field{*\fldinst SYMBOL 98 \f "Symbol"
 \par Rho-dependent adhesion)
 \par IT Laminins
 \par (adhesion to; activation of protein kinase C by phorbol esters

modulates }{\f2\fs20 {\field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2
MCF-7 }{\b\fs20\cf6 breast}{\f2\fs20 cancer cells by altering gene expression of
}{\f2\fs20 {\field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2
97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2\fs20 {\field{*\fldinst SYMBOL 98 \f "Symbol"
Rho-dependent adhesion)
\par IT Collagens, biological studies
\par (type I, adhesion to; activation of protein kinase C by phorbol
esters modulates }{\f2\fs20 {\field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2
human MCF-7 }{\b\fs20\cf6 breast}{\f2\fs20 cancer cells by altering gene
expression of }{\f2\fs20 {\field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2
}{\f2\fs20 {\field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2\fs20 {\f2
\par IT Integrins
\par ({\f2\fs20 {\field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2
modulates }{\f2\fs20 {\field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2
MCF-7 }{\b\fs20\cf6 breast}{\f2\fs20 cancer cells by altering gene expression of
}{\f2\fs20 {\field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2
97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2\fs20 {\field{*\fldinst SYMBOL 98 \f "Symbol"
Rho-dependent adhesion)
\par IT 9059-32-9, GTPase
\par (Rho; activation of protein kinase C by phorbol esters modulates
}{\f2\fs20 {\field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2
}{\b\fs20\cf6 breast}{\f2\fs20 cancer cells by altering gene expression of
}{\f2\fs20 {\field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2
97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2\fs20 {\field{*\fldinst SYMBOL 98 \f "Symbol"
Rho-dependent adhesion)
\par IT 141436-78-4, Protein kinase C
\par (activation of protein kinase C by phorbol esters modulates
}{\f2\fs20 {\field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2
}{\b\fs20\cf6 breast}{\f2\fs20 cancer cells by altering gene expression of
}{\f2\fs20 {\field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2
97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2\fs20 {\field{*\fldinst SYMBOL 98 \f "Symbol"
Rho-dependent adhesion)
\par IT 16561-29-8, TPA (phorbol derivative)
\par (activation of protein kinase C by phorbol esters modulates
}{\f2\fs20 {\field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2
}{\b\fs20\cf6 breast}{\f2\fs20 cancer cells by altering gene expression of
}{\f2\fs20 {\field{*\fldinst SYMBOL 97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2
97 \f "Symbol" \s 10}{\fldrslt\fs3\fs20}}}{\f2\fs20 2}{\f2\fs20 {\field{*\fldinst SYMBOL 98 \f "Symbol"
Rho-dependent adhesion)
\par REFERENCE COUNT: 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR
\par THIS RECORD. ALL CITATIONS AVAILABLE IN THE
\par RE FORMAT
\par
\par L106 ANSWER 7 OF 43 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 10
\par ACCESSION NUMBER: 1994:694736 HCAPLUS }{\field{*\fldinst {\f2\fs20 HYPERLINK "http://
chemport.cas.org/cgi-bin/ex_sdcgi?uuZguK@1ruxN9uqgdMVT Rx59jvJ1QBumfxaczUW0JM3I@11ZCme@YJpnmQJF3AU4RnrIyLvn5
00d0c9ea79f9bacell18c8200aa004ba90b0200000003000000e0c9ea79f9bacell18c8200aa004ba90bd801000068007400740070003
750075005a00670075004b00400031007200750078004e00390075007100710064004d005600540052007800350039006a0076004ac
0052006e007200490079004c0076006e003500400031005500700076006b0071004600590052003300710078006b005700420043007
6a00680075007000480053004c00340040005a004d006b00580065007800710039003600710078006b005500510046003300480067c
007200400078000000}}}{\fldrslt {\f2\fs20\ul\cf2 Full-text}}}{\v\fs20 <<LOGINID::20061206>>}{\f2\fs20
\par DOCUMENT NUMBER: 121:294736
\par TITLE: Delaying toxigenesis of Clostridium
\par }{\b\fs20\cf6 botulinum}{\f2\fs20 by sodium lactate in "sous-vide"
\par products
\par AUTHOR(S): Meng, J.; Genigeorgis, C. A.
\par CORPORATE SOURCE: School Veterinary Medicine, University California,
\par Davis, CA, USA
\par SOURCE: Letters in Applied Microbiology ({\b\fs20\cf6 1994}{\f2\fs20 },
\par }{\f2\fs20\lang1036\langfel033\langnpl036 19(1), 20-3
\par CODEN: LAMIE7; ISSN: 0266-8254
\par }{\f2\fs20 DOCUMENT TYPE: Journal
\par LANGUAGE: English
\par ED Entered STN: 24 Dec 1994
\par }{\pard \ql \fi-666\li666\ri0\widctlpar\tx666\faauto\adjustright\ri0\lin666\itap0 {\f2\fs20 AB \tab Th
\fs20 spores inoculated in processed "sous-vide"-type beef, chicken }{\b\fs20\cf6 breast}{\f2\fs20
}{\f2\fs20 in the "sous-vide" products.
\par }{\pard \ql \li0\ri0\nowidctlpar\faauto\ri0\lin0\itap0 {\f2\fs20 CC 4-5 (Toxicology)
\par Section cross-reference(s): 10
\par IT }{\b\fs20\cf6 Clostridium botulinum}{\f2\fs20
\par Food contamination
\par Spore
\par Temperature effects, biological
\par (sodium lactate effect on toxigenesis of Clostridium
\par }{\b\fs20\cf6 botulinum}{\f2\fs20 spore in sous-vide products)
\par IT Meat

```

\par      (beef, sodium lactate effect on toxigenesis of Clostridium
\par      ){\b\f2\fs20\cf6 botulinum}{\f2\fs20  spore in sous-vide products)
\par IT   Meat
\par      (chicken, ){\b\f2\fs20\cf6 breast}{\f2\fs20 ; sodium lactate effect on toxigenesis of
\par      Clostridium }{\b\f2\fs20\cf6 botulinum}{\f2\fs20  spore in sous-vide products)
\par IT   Temperature effects, biological
\par      (cold, sodium lactate effect on toxigenesis of Clostridium
\par      ){\b\f2\fs20\cf6 botulinum}{\f2\fs20  spore in sous-vide products)
\par IT   Poisoning
\par      (food, sodium lactate effect on toxigenesis of Clostridium
\par      ){\b\f2\fs20\cf6 botulinum}{\f2\fs20  spore in sous-vide products)
\par IT   Salmon
\par      (meal, sodium lactate effect on toxigenesis of Clostridium
\par      ){\b\f2\fs20\cf6 botulinum}{\f2\fs20  spore in sous-vide products)
\par IT   50-21-5, Lactic acid, biological studies 72-17-3, Sodium lactate
\par      (sodium lactate effect on toxigenesis of Clostridium
\par      ){\b\f2\fs20\cf6 botulinum}{\f2\fs20  spore in sous-vide products)
\par
\par L106 ANSWER 8 OF 43 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 11
\par ACCESSION NUMBER:      1993:492180 HCAPLUS ){\field{*}\fldinst {\f2\fs20 HYPERLINK "http://chem
port.cas.org/cgi-bin/ex_sdcgi?uuZguK@lruxN9uqEdMvTRx59jvJlQBumfxaczUW0JM3I@1I2Cme@YJpnmQJF3AU4RnrIyLvn5@1Ug
00d0c9ea79f9bace118c8200aa004ba90b0200000003000000e0c9ea79f9bace118c8200aa004ba90bd801000068007400740070003
750075005a00670075004b00400031007200750078004e00390075007100450064004d005600540052007800350039006a0076004ac
0052006e007200490079004c0076006e003500400031005500700076006b0030004600590052003300710078006b005700420043007
6a00680075007000480053004c00340040005a004d007500580065007800710039003600710078006b005500510046003300480034c
007200400078000000}}{\fldrslt {\f2\fs20\ul\cf2 Full-text}}{\v\f2\fs20 <<LOGINID::20061206>>}{\f2\fs20
\par DOCUMENT NUMBER:      119:92180
\par TITLE:                Low molecular mass GTP-binding proteins are
\par                        secreted from ){\b\f2\fs20\cf6 mammary}{\f2\fs20 }{\b\f2\fs20\cf6 epithelial
\par                        cells in association with lipid globules
\par AUTHOR(S):            Ghosal, Debabrota; Ankrapp, David; Keenan, Thomas
\par                        W.
\par CORPORATE SOURCE:     Department of Biochemistry and Nutrition, Virginia
\par                        Polytechnic Institute and State University,
\par                        Blacksburg, VA, USA
\par SOURCE:               Biochimica et Biophysica Acta, Lipids and Lipid
\par                        Metabolism ){\b\f2\fs20\cf6 1993}{\f2\fs20 }, 1168(3), 299-306
\par CODEN: BBLA6; ISSN: 0005-2760
\par PUBLISHER:            Elsevier B.V.
\par DOCUMENT TYPE:        Journal
\par LANGUAGE:             English
\par ED Entered STN:       04 Sep 1993
\par }}\pard \ql \fi-666\li666\ri0\widctlpar\tx666\faauto\adjustright\rin0\lin666\itap0 {\f2\fs20 AB \tab Se
alized region of apical plasma membrane of ){\b\f2\fs20\cf6 mammary}{\f2\fs20 }{\b\f2\fs20\cf6 epithelial}
cells. A class of low mol. mass GTP-binding proteins were associated tightly with the lipid globule membr
during intracellular growth and transit of lipid globule precursors. Inclusion of GTP or GTP){\f2\fs20 {
S in incubation medium stimulated secretion of lipids from primary cultures of permeabilized rat ){\b\f2\fs
ypeptides with mol. masses between 28 and 21 kDa were detected by ability to bind GTP){\f2\fs20 {\field{*}\
S following separation of lipid-globule-associated proteins by SDS-PAGE and transblotting onto nitrocellul
es were distinct immunol. from the archetype ras was evident from lack of immunoreactivity with p21ras G-pr
GTP){\f2\fs20 {\field{*}\fldinst SYMBOL 103 \f "Symbol" \ls 10}{\fldrslt{\f3\fs20}}}{\f2\fs20 S binding as
\b\f2\fs20\cf6 toxin){\f2\fs20 C3, but cholera toxin was much less effective, suggesting that this compone
\par }}\pard \ql \li0\ri0\nowidctlpar\faauto\rin0\lin0\itap0 {\f2\fs20 CC 13-6 (Mammalian Biochemistry)
\par IT ){\b\f2\fs20\cf6 Mammary gland}{\f2\fs20
\par      (epithelium, G proteins secreted by cells of, in association with lipid
\par      globules)
\par IT   G proteins (guanine nucleotide-binding proteins)
\par      (low-mol.-weight, secretion of, by ){\b\f2\fs20\cf6 mammary}{\f2\fs20
\par      ){\b\f2\fs20\cf6 epithelial}{\f2\fs20  cells in association with lipid globules)
\par IT   Fats and Glyceridic oils
\par      (milk, globule membrane of, secretion of, by ){\b\f2\fs20\cf6 mammary}{\f2\fs20
\par      ){\b\f2\fs20\cf6 epithelial}{\f2\fs20  cells, G proteins associated with)
\par IT   Biological transport
\par      (secretion, of GTP-binding proteins by ){\b\f2\fs20\cf6 mammary}{\f2\fs20
\par      ){\b\f2\fs20\cf6 epithelial}{\f2\fs20  cells in association with lipid globules)
\par
\par L106 ANSWER 9 OF 43 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 12
\par ACCESSION NUMBER:      1994:296952 HCAPLUS ){\field{*}\fldinst {\f2\fs20 HYPERLINK
"http://chemport.cas.org/cgi-bin/ex_sdcgi?uuZguK@lruxN9uq@dMvTRx59jvJlQBumfxaczUW0JM3I@1IECme@YJpnmQJF3AU4
}{*\datafield
00d0c9ea79f9bace118c8200aa004ba90b0200000003000000e0c9ea79f9bace118c8200aa004ba90bd801000068007400740070003
750075005a00670075004b00400031007200750078004e00390075007100450064004d005600540052007800350039006a0076004ac
0052006e007200490079004c0076006e003500400031005500700076006b0070004600590052003300710078006b005700420043007
6a00680075007000480053004c00340040005a004d006c00580065007800710039003600710078006b005500510046003300480067c
007200400078000000}}{\fldrslt {\f2\fs20\ul\cf2 Full-text}}{\v\f2\fs20 <<LOGINID::20061206>>}{\f2\fs20
\par DOCUMENT NUMBER:      120:296952

```

\par TITLE: Development and use of probability models: the
 \par industry perspective
 \par AUTHOR(S): Maas, Melanie R.
 \par CORPORATE SOURCE: Res. Dev., Oscar Mayer Foods Corp., Madison, WI,
 \par 53707, USA
 \par SOURCE: Journal of Industrial Microbiology (}{\b\f2\fs20\cf6 1993}{\f2\fs20
 \par), 12(3-5), 162-7
 \par CODEN: JIMIE7; ISSN: 0169-4146
 \par DOCUMENT TYPE: Journal
 \par LANGUAGE: English
 \par ED Entered STN: 11 Jun 1994
 \par }}\pard \ql \fi-666\li666\ri0\widctlpar\tx666\faauto\adjustright\rin0\lin666\itap0 {\f2\fs20 AB \tab Ir
 use of probability modeling. The effectiveness of sodium lactate as an antibotulinal agent in vacuum pack
 containing 1.4% NaCl, 0.3% Na phosphate, and 0-3% Na lactate, the antibotulinal effect of sodium lactate c
 with 0.3% Na phosphate, 0.2% sucrose, 0-3% Na lactate, the time to toxicity can be predicted
 from the following model: days to toxicity = 1.69 + 4.88(NaCl) - 11.16(Na lactate) + 7.23(Na lactate)2. F
 tive modeling for food safety and quality in the food industry is also discussed.
 \par }}\pard \ql \li0\ri0\nowidctlpar\faauto\rin0\lin0\itap0 {\f2\fs20 CC 17-4 (Food and Feed Chemistry) ,
 \par ST turkey contamination }{\b\f2\fs20\cf6 botulin}{\f2\fs20 model
 \par IT Simulation and Modeling, biological
 \par (of }{\b\f2\fs20\cf6 botulin}{\f2\fs20 formation in turkey)
 \par IT Meat
 \par (turkey, }{\b\f2\fs20\cf6 botulin}{\f2\fs20 formation in, sodium lactate effect on,
 \par probability model of)
 \par IT 72-17-3, Sodium lactate

[start](#) | [next page](#)
